<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a fatal marrow disorder distinct from primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the efficacy of bone marrow transplantation (BMT) as a treatment for patients with <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Eighteen patients with <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> and twenty-five patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> received an allogeneic, syngeneic, or unrelated donor BMT </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> prophylaxis included <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> plus <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, FK-506, or T cell <z:mpath ids='MPATH_63'>depletion</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Conditioning regimens consisted of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>/total body irradiation, with and without <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, <z:chebi fb="0" ids="28901">busulfan</z:chebi>/<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>/<z:chebi fb="0" ids="4911">etoposide</z:chebi>/<z:chebi fb="0" ids="3423">carmustine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>For patients with <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e>, the median age was 32 years and the actuarial disease-free survival was 24% (95% confidence interval 6, 42%) with a median follow-up of 3 years </plain></SENT>
<SENT sid="6" pm="."><plain>For patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the median age was 36 years and the actuarial disease-free survival at 3 years was 43% (95% confidence interval 22, 64%) </plain></SENT>
<SENT sid="7" pm="."><plain>Four of the therapy-related patients and two of the primary patients have relapsed </plain></SENT>
<SENT sid="8" pm="."><plain>Three patients experienced graft failure; <z:hpo ids='HP_0000001'>all</z:hpo> three had received T cell-depleted marrow and two had marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Our results suggest that patients with <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> can be successfully transplanted </plain></SENT>
<SENT sid="10" pm="."><plain>Transplantation should be considered early in the disease, since long-term disease-free survival is achievable </plain></SENT>
</text></document>